Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | DAO | P14920 | 1/20 | 0.70 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.70 |
| ▸ | CES1 | P23141 | 5/20 | 0.62 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.58 |
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL23753263 | 1.00 | TSHR (0.70) | TSHRDAONAPRTCES1SRD5A2 | |
| Terephthalic Acid SCHEMBL8370036 | 0.90 | TSHR (0.67) | TSHRDAONAPRTCES1SRD5A2 | |
| Trifluoroacetic Acid SCHEMBL6620503 | 0.87 | EGFR (0.58) | TSHRDAONAPRTCES1SRD5A2 | |
| Benzoic Acid SCHEMBL28034108 | 0.86 | TSHR (0.64) | TSHRDAONAPRTCES1SRD5A2 | |
| Benzoic Acid SCHEMBL28286739 | 0.86 | TSHR (0.64) | TSHRDAONAPRTCES1SRD5A2 | |
| Benzophenone SCHEMBL27658893 | 0.85 | ALDH1A1 (0.70) | TSHRDAONAPRTCES1SRD5A2 | |
| Benzoic Acid SCHEMBL21747702 | 0.85 | TSHR (0.70) | TSHRDAONAPRTCES1SRD5A2 | |
| Benzoic Acid SCHEMBL3364736 | 0.85 | TSHR (0.70) | TSHRDAONAPRTCES1SRD5A2 | |
| Benzoic Acid SCHEMBL28397394 | 0.84 | TSHR (0.88) | TSHRDAONAPRTCES1SRD5A2 | |
| Benzoic Acid SCHEMBL976149 | 0.84 | TSHR (1.00) | TSHRDAONAPRTCES1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794009-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | Kancera AB (SE) | 2014-10-29 | — | — | EP | claimed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | claimed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| WO-2025224599-A1 | PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| US-20240228444-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | RECURSION PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-118084904-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-113336697-B | CDK9 inhibition compound and application thereof | 厦门大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-111801327-B | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117263988-A | Method for preparing tetravalent platinum medicine from hydroxyl-containing organic matter, tetravalent platinum medicine and application of tetravalent platinum medicine | 深圳大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-2075261-A1 | 6-Position highly acetylated cellulose diacetate and process for producing the same | Daicel Chemical Industries, Ltd. (JP) | 2009-07-01 | — | — | EP | disclosed |
| CN-101472925-A | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| US-6289196-B1 | Oxidized transport donor roll coatings | XEROX CORPORATION | 2001-09-11 | — | — | US | disclosed |
| EP-1073624-A1 | AMINOMETHYL-BENZOIC ESTER DERIVATIVES AS TRYPTASE INHIBITORS | Proteus Molecular Design Limited (GB) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055661-A1 | AMINOMETHYL-BENZOIC ESTER DERIVATIVES AS TRYPTASE INHIBITORS | PROTEUS MOLECULAR DESIGN LIMITED (GB) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228444-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | CYP11B2, CYP11B1, MAPT | TSHR 2905/4885DAO 1884/4885NAPRT 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.